Ticagrelor: The silence of the platelets

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 2, 2013, Pages 151-153

  Laine, Marc ^a   Paganelli, Franck ^a   Bonello, Laurent ^a,b  

^a HÔPITAL NORD   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Acute coronary syndrome; Major adverse cardiac events; Percutaneous coronary syndrome; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ATAZANAVIR; CLARITHROMYCIN; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; KETOCONAZOLE; NEFAZODONE; PRASUGREL; RITONAVIR; TICAGRELOR;

ACUTE CORONARY SYNDROME; BLEEDING; BODY WEIGHT; BRADYCARDIA; BRAIN HEMORRHAGE; CARDIOVASCULAR MORTALITY; CORONARY ARTERY BYPASS GRAFT; DRUG COST; DRUG EFFICACY; DRUG TRANSFORMATION; DYSPNEA; EDITORIAL; GERIATRIC PATIENT; GOLD STANDARD; HUMAN; KIDNEY FUNCTION; LOADING DRUG DOSE; LOW DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PRESCRIPTION; SIDE EFFECT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE; THROMBOCYTE ACTIVATION; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADENOSINE; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS;

EID: 84872740795     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.758252     Document Type: Editorial

References (13)

1. James SK, Roe MT, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ 2011;342:d3527-7
2. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New Engl J Med 2009;361(11):1045-57
3. Bliden KP, Tantry US, Storey RF, et al. The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. Am Heart J 2011;162(1):160-5
4. Alexopoulos D, Galati A, Xanthopoulou I, et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention. J Am Coll Cardiol 2012;60(3):193-9
5. James SK, Storey RF, Khurmi NS, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation 2012;125(23):2914-21
6. Husted S, James S, Becker RC, et al. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) Trial. Circ Cardiovasc Qual Outcomes 2012;5(5):680-8
7. Authors/Task Force Members. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012;33(20):2569-619
8. Nikolic E, Janzon M, Hauch O, et al. Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. Eur Heart J 2012, doi: 10.1093/eurheartj/ehs149
9. Cattaneo M, Faioni EM. Why does ticagrelor induce dyspnea? Thromb Haemost 2012;108(6):1031-6
10. Dinicolantonio JJ, Serebruany VL. Angiotensin receptor blockers worsen renal function and dyspnea on ticagrelor: a potential ticagrelor-angiotensin receptor blocker interaction? Clin Cardiol 2012;35(11):647-8
11. Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention clinical perspective a platelet inhibition and patient outcomes (PLATO) trial subgroup analysis. Circulation 2010;122(21):2131-41
12. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009;373(9665):723-31
13. Berger PB, Bhatt DL, Fuster V, et al. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) Trial. Circulation 2010;121(23):2575-83